CollPlant

112 articles about CollPlant

• CollPlant to Present at the H.C. Wainwright Annual Growth Conference

  9/5/2023

  CollPlant Biotechnologies, a regenerative and aesthetics medicine company developing innovative technologies and products based on its non-animal-derived collagen for tissue regeneration and organ manufacturing, announced that it will participate at the H.C Wainwright Annual Growth Conference, to be held from September 11-13, 2023 in New York, NY.

• COLLPLANT BIOTECHNOLOGIES ANNOUNCES DATE FOR 2022 FIRST QUARTER FINANCIAL RESULTS AND CONFERENCE CALL INFORMATION

  8/9/2023

  CollPlant Biotechnologies today announced that it will report financial results for the second quarter of 2023 on Thursday, August 24, 2023, before the market open. 

• CollPlant Biotechnologies Announces First Quarter Financial Results For 2023 and Provides Corporate Update

  5/24/2023

  CollPlant Biotechnologies today announced financial results for the first quarter ended March 31, 2023, and provided a corporate update on its programs.

• Collplant Biotechnologies Announces Date for 2023 First Quarter Financial Results and Conference Call Information

  5/2/2023

  CollPlant Biotechnologies announced that it will report financial results for the first quarter of 2023 on May 24, 2023, before the market open.

• Stratasys and CollPlant Unite Technologies to Transform Healthcare with Industrial-Scale Bioprinting of Tissues and Organs

  4/4/2023

  Stratasys Ltd. and CollPlant Biotechnologies announced a joint development and commercialization agreement to collaborate on the development of a solution to bio-fabricate human tissues and organs using Stratasys’ P3 technology-based bioprinter and CollPlant’s rh-Collagen-based bioinks.

• Collplant Biotechnologies Announces Full-Year Financial Results For 2022 and Provides Corporate Update

  3/29/2023

  CollPlant Biotechnologies today announced financial results for the full year ended December 31, 2022 and provided a corporate update on its programs.

• COLLPLANT BIOTECHNOLOGIES ANNOUNCES DATE FOR 2022 FULL YEAR FINANCIAL RESULTS AND CONFERENCE CALL INFORMATION

  3/14/2023

  CollPlant Biotechnologies today announced that it will report financial results for the full year ended December 31, 2022, on March 29, 2023, before the market open. 

• CollPlant Issues Letter to Shareholders - January 24, 2023

  1/24/2023

  CollPlant is pleased to issue the following letter from its Chief Executive Officer, Yehiel Tal, to its shareholders.

• CollPlant Enriches Portfolio of rhCollagen-Based Bioinks with Launch of Collink.3DTM 50L in Powder Form

  1/3/2023

  CollPlant today announced the launch of Collink.3DTM 50L, a recombinant human collagen (rhCollagen)-based bioink in a powder form for use in a wide range of 3D bioprinting applications, including drug discovery, drug screening, tissue testing as well as the development of transplantable tissues and organs.

• CollPlant Biotechnologies Provides Business Updates and Third Quarter 2022 Financial Results

  12/1/2022

  CollPlant Biotechnologies (Nasdaq: CLGN), a regenerative and aesthetic medicine company developing innovative human collagen-based technologies and products for tissue regeneration and organ manufacturing, today announced financial results for the third quarter ended September 30, 2022 and provided an update on the Company's business developments.

• CollPlant Expands rhCollagen-Based Bioink Platform with Launch of Collink.3D™ 90

  11/7/2022

  CollPlant today announced the Company is launching Collink.3D™ 90, a recombinant human collagen (rhCollagen)-based bioink for use in a variety of 3D bioprinting applications.

• CollPlant to Present at Canaccord Genuity MedTech, Diagnostics and Digital Health & Services Forum on November 17

  11/3/2022

  CollPlant Biotechnologies announced that Eran Rotem, Collplant's Deputy CEO and Chief Financial Officer, will present a company overview at the Canaccord Genuity MedTech, Diagnostics and Digital Health & Services Forum at the Westin NY Grand Central Hotel.

• CollPlant to present at the Dawson James Small Cap Growth Conference on October 12

  10/3/2022

  CollPlant Biotechnologies today announced that the Company's Deputy CEO & Chief Financial Officer Eran Rotem will present a company overview at the Dawson James 7th Annual Small Cap Growth Conference at the Wyndham Grand Hotel in Jupiter, Florida.

• CollPlant to Present at the International Conference on Biofabrication 2022 in Tuscany, Italy

  9/19/2022

  CollPlant today announced the Company will make a presentation on "Recombinant Human Collagen-based Bioinks for Biofabrication and Modeling Applications" at the International Conference on Biofabrication on September 28th.

• CollPlant Biotechnologies to Participate in September 2022 Investor Conferences

  9/6/2022

  CollPlant Biotechnologies announced that Deputy CEO and CFO Eran Rotem will participate in investor conferences later this month.

• CollPlant Biotechnologies Provides Business Updates and Second Quarter 2022 Financial Results

  8/25/2022

  CollPlant Biotechnologies (NASDAQ: CLGN), a regenerative and aesthetic medicine company developing innovative human collagen-based technologies and products for tissue regeneration and organ manufacturing, today announced financial results for the second quarter ended June 30, 2022 and provided an update on the Company's business developments.

• CollPlant to Present and Exhibit at TERMIS Annual Conference in Toronto, Canada

  7/5/2022

  CollPlant today announced that the company will deliver two presentations, and will have an exhibition booth at the annual conference and exhibition of the Tissue Engineering and Regenerative Medicine International Society (TERMIS), in Toronto, Canada, on July 10-13, 2022.

• CollPlant Advances its 3D Bioprinted Regenerative Breast Implants into Porcine Study

  6/29/2022

  CollPlant today announced the initiation of a study in large animals for its 3D bioprinted regenerative breast implant program, addressing the $2.8 billion global breast implant market.

• CollPlant Biotechnologies Provides Business Updates and First Quarter 2022 Financial Results

  5/26/2022

  CollPlant Biotechnologies (NASDAQ: CLGN), a regenerative and aesthetic medicine company developing innovative technologies and products for tissue regeneration and organ manufacturing, today announced business updates and financial results for the first quarter ended March 31, 2022.

• CollPlant To Present at the Aesthetics Innovation Summit 2022

  4/13/2022

  CollPlant today announced that Dr. Jasmine Seror, CollPlant's Head of Aesthetic Medicine and Exploratory Products, will deliver a presentation at the Aesthetics Innovation Summit 2022, to be held in San Diego, California, on Wednesday, April 20, 2022.